Soligenix Inc
SNGX3.200USD
+0.460+16.79%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
10.19MCap. mercado
PérdidaP/E TTM
Más Datos de Soligenix Inc Compañía
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
Información de la empresa
Símbolo de cotizaciónSNGX
Nombre de la empresaSoligenix Inc
Fecha de salida a bolsaApr 04, 1994
Director ejecutivoDr. Christopher J. (Chris) Schaber, Ph.D.
Número de empleados14
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 04
Dirección29 Emmons Drive
CiudadPRINCETON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal08540
Teléfono16095388200
Sitio Webhttps://www.soligenix.com/
Símbolo de cotizaciónSNGX
Fecha de salida a bolsaApr 04, 1994
Director ejecutivoDr. Christopher J. (Chris) Schaber, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
379.00
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Jonathan L. Guarino, CPA
Mr. Jonathan L. Guarino, CPA
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
379.00
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Connective Capital Management, LLC
3.11%
Geode Capital Management, L.L.C.
0.90%
UBS Financial Services, Inc.
0.32%
Morgan Stanley Smith Barney LLC
0.11%
The Vanguard Group, Inc.
0.10%
Other
95.46%
Accionistas
Accionistas
Proporción
Connective Capital Management, LLC
3.11%
Geode Capital Management, L.L.C.
0.90%
UBS Financial Services, Inc.
0.32%
Morgan Stanley Smith Barney LLC
0.11%
The Vanguard Group, Inc.
0.10%
Other
95.46%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
3.11%
Investment Advisor/Hedge Fund
0.90%
Investment Advisor
0.54%
Individual Investor
0.02%
Other
95.43%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
50
149.55K
4.58%
-122.83K
2025Q1
50
149.55K
4.59%
-122.83K
2024Q4
62
34.48K
1.37%
-224.66K
2024Q3
62
66.84K
2.91%
-140.04K
2024Q2
61
101.18K
6.59%
-9.86K
2024Q1
57
15.87K
2.48%
-90.98K
2023Q4
55
24.60K
3.87%
-67.56K
2023Q3
57
57.20K
9.40%
-37.02K
2023Q2
61
91.32K
18.32%
+80.79K
2023Q1
62
7.29K
3.99%
-8.64K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Connective Capital Management, LLC
101.63K
3.11%
+101.63K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
29.37K
0.9%
+3.27K
+12.55%
Mar 31, 2025
UBS Financial Services, Inc.
10.47K
0.32%
+10.16K
+3244.73%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
3.59K
0.11%
-1.00
-0.03%
Mar 31, 2025
The Vanguard Group, Inc.
3.18K
0.1%
--
--
May 31, 2025
Schaber (Christopher J)
379.00
0.01%
--
--
Apr 21, 2025
Plante Moran Financial Advisors, LLC
300.00
0.01%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
223.00
0.01%
--
--
Mar 31, 2025
Zeldis (Jerome B)
96.00
0%
--
--
Apr 21, 2025
Northern Trust Investments, Inc.
72.00
0%
+72.00
--
Dec 31, 2023
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Fecha
Tipo
Relación
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Apr 29, 2024
Merger
16<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
Feb 09, 2023
Merger
15<1
